Preventing or delaying the onset of end-stage kidney disease is vital. By implementing a results-driven, value-based approach, Dallas Nephrology Associates has demonstrated improved patient outcomes and value for payers.
Belinda Tommey, MHA
Advertisement
Articles by Belinda Tommey, MHA
Advertisement
Latest Updated Articles
Dallas Nephrology Associates’ Journey to Value-Based CareDecember 10th 2024
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access
5